{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:13:52Z","timestamp":1779236032110,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.diagmicrobio.2015.01.015","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T07:19:36Z","timestamp":1423552776000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013"],"prefix":"10.1016","volume":"82","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0005","series-title":"M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0010","series-title":"M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2015.01.015_bb0015","first-page":"iii45","article-title":"Review of ceftaroline fosamil microbiology: integrated FOCUS studies","volume":"66","author":"Critchley","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2015.01.015_bb0020","first-page":"iii35","article-title":"Complicated skin and soft tissue infection","volume":"65","author":"Dryden","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2015.01.015_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1469-0691.2006.01395.x","article-title":"Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia","volume":"12","author":"File","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0035","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.02557-13","article-title":"Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers","volume":"58","author":"Flamm","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.diagmicrobio.2013.10.020","article-title":"Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009\u20132011","volume":"78","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0045","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-013-0075-6","article-title":"Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia","volume":"73","author":"Frampton","year":"2013","journal-title":"Drugs"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2015.01.015_bb0050","first-page":"iii69","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0055","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1128\/AAC.01485-13","article-title":"In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study","volume":"57","author":"Karlowsky","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0060","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care\u2013associated pneumonia: results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0065","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2165\/11635660-000000000-00000","article-title":"Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"72","author":"Lodise","year":"2012","journal-title":"Drugs"},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2015.01.015_bb0070","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1093\/cid\/cis561","article-title":"AWARE ceftaroline surveillance program (2008\u20132010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States","volume":"55","author":"Pfaller","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.diagmicrobio.2013.08.027","article-title":"Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009\u20132011)","volume":"78","author":"Pfaller","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0080","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0085","unstructured":"Teflaro\u2122 Package Insert 2012. New York City, NY. Available at http:\/\/www.frx.com\/pi\/Teflaro_pi.pdf. Accessed August 2013."},{"key":"10.1016\/j.diagmicrobio.2015.01.015_bb0090","unstructured":"Tygacil\u00ae Package Insert 2012. Wyeth Pharmaceuticals, Philadelphia, PA. Available at www.tygacil.com."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T09:51:40Z","timestamp":1537869100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889315000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0732889315000310"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.01.015","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}